Alzheimer's disease is the most common cause of dementia and, while no current medication can stop the underlying neurodegeneration, four classes of evidence-based therapy can stabilise cognitive function for typically 6–18 months at each disease stage. The right choice depends on whether the disease is mild, moderate ή σοβαρές, and whether the patient also has Parkinson's disease dementia.
MedsBase stocks all four mainstream Alzheimer's medications. Donepezil — the most-prescribed AChE inhibitor worldwide and the only one licensed across mild, moderate και severe disease — is available as Aricep (5 mg + 10 mg), Donect (10 mg) and Donemax (10 mg). Memantine, the NMDA antagonist used for moderate-to-severe disease and standard add-on to donepezil, is stocked as Αντμέντα (5 mg, titrated over 4 weeks to 20 mg/day maintenance). Galantamine — a dual-mechanism AChE inhibitor + nicotinic receptor modulator for mild-to-moderate disease — is stocked as Galamer (4 mg). Rivastigmine, the only cholinesterase inhibitor with an on-label indication for Parkinson's disease dementia, is stocked as Rivamer (1.5 mg).
This page lists prescription-only medications that should be initiated and monitored by a doctor. All four drugs require slow upward titration over 4–8 weeks, formal cognitive re-assessment at 6 months, and never abrupt discontinuation. Caregiver supervision of dosing is essential for safety. Please read the individual product page for full dosing, monitoring, and safety information before ordering.